Published Evidence for Value-Based Insurance Design Michael C. Sokol, MD, MS Corporate Medical Director Merck & Co., Inc.

Slides:



Advertisements
Similar presentations
Jack Jedwab Association for Canadian Studies September 27 th, 2008 Canadian Post Olympic Survey.
Advertisements

BBFI Group Benefits Committee
Egyptian Perspective On Prediabetes & Diabetes
1 January 5, 2014 ©Copyright 2010 Jacqueline Madrigal Benefits Manager.
Ten years of the CHD NSF Professor Roger Boyle CBE National Director for Heart Disease and Stroke Department of Health.
1 Changing Profile of Household Sector Credit and Deposits in Indian Banking System -Deepak Mathur November 30, 2010.
Ensuring financial sustainability of health system in Estonia Hannes Danilov Head of Management Board JOINT OECD AND WHO MEETING ON FINANCIAL SUSTAINABILITY.
MDG Target 8.E gap analysis Ms. Alexandra Cameron Department of Essential Medicines and Pharmaceutical Policies, World Health Organization 27 August 2008.
Solving the Faculty Shortage in Allied Health 9 th Congress of Health Professions Educators 4 June 2002 Ronald H. Winters, Ph.D. Dean College of Health.
Understanding Changes in Local Public Health Spending Glen Mays, PhD, MPH Department of Health Policy and Management University of Arkansas for Medical.
Paying for Care Coordination Gerard Anderson, PhD Johns Hopkins University.
The Impact of Drug Benefit Caps Geoffrey Joyce, PhD.
Sharon Moffatt RN MSN Acting Commissioner of Health November 6, 2006.
TABLE OF CONTENTS CHAPTER 1.0: Trends in the Overall Health Care Market Chart 1.1: Total National Health Expenditures, 1980 – 2005 Chart 1.2: Percent Change.
THE COMMONWEALTH FUND Figure 1. Health Insurance Coverage and Uninsured Trends Data: Analysis of the U.S. Census Bureau, Current Population Survey Annual.
Common Wealth Fund Webinar February 5, 2013
State & Local Governments
THE COMMONWEALTH FUND 1 An Estimated 116 Million Adults Were Uninsured, Underinsured, Reported a Medical Bill Problem, and/or Did Not Access Needed Health.
Lessons Learned through Research: Do Hospitals and Ambulatory Centers Follow Guideline Recommended Care Nancy Albert, PhD, RN, CCNS, CCRN, NE-BC, FAHA,
Promising Practices Related To The Prevention, Control and Treatment of Hypertension David J. Hyman, MD, MPH Professor of Medicine and Family & Community.
The Vermont Health Care Commission 2005 Future Directions for Health Care Reform in Vermont Kenneth E. Thorpe, Ph.D. Robert W. Woodruff Professor and Chair.
Minnesota Health Care Market Trends and Strategies for Cost Containment Health Care Transformation Task Force July 30, 2007 Julie Sonier Director, Health.
Epidemiology and Outcomes of IA in the 21st Century: Strengths and Weaknesses of Surveillance Databases Dionissios Neofytos, MD, MPH Transplant & Oncology.
What You Wanted to Know About Formularies Emmanuelle Mirsakov Pharm.D. Candidate 2007 USC School Of Pharmacy.
Connecticuts Value Based Insurance Design The Health Enhancement Program for Connecticut State Employees (Covers Active State Employees and Retirees After.
Overview of Rural Health Care Ethics Training materials from Rural Health Care Ethics: A Manual for Trainers. WA Nelson and KE Schifferdecker, Dartmouth.
Break Time Remaining 10:00.
1 Exploration of Health Care Providers Behavior to Keep Their Revenues after Reduction of Payment Generosity --- A Case of Drug Payment in Taiwan Likwang.
Sexual Behaviors that Contribute to Unintended Pregnancy and Sexually Transmitted Infections, Including HIV Infection.
Scientific Research Showing Reductions in Medical Expenses from Transcendental Meditation Practice and Maharishi Vedic Approach to Health By Robert E.
Nurse Led Clinics Opportunity for nurses to make a difference Wilma Scholte op Reimer, RN, PhD Amsterdam School of Health Professions Academic Medical.
HOW THE NON-STATE SECTOR ENGAGE TO STEWARDSHIP OF MIXED SYSTEM IN IN VIETNAM Health Strategy and Policy Institute - Vietnam.
Before Between After.
7/16/08 1 New Mexico’s Indicator-based Information System for Public Health Data (NM-IBIS) Community Health Assessment Training July 16, 2008.
Minimum Creditable Coverage Policy Committee Meeting January 19, 2007.
ADVANCING HEALTH CARE QUALITY IN 2007 AND BEYOND Margaret E. O’Kane President, NCQA.
ADVANCING HEALTH CARE QUALITY IN 2007 AND BEYOND Margaret E. O’Kane President National Committee for Quality Assurance.
Clock will move after 1 minute
F. Randy Vogenberg, PhD, RPh
Patient adherence in type 2 diabetes: What’s the issue and how to address it Anthony Barnett University of Birmingham and Heart of England NHS Foundation.
Pharmacist Assisting at Routine Medical Discharge: Project PhARMD
Defining Value in Cancer Care. US Supreme Court Passes the Affordable Care Act (Obama-care) all in US will either have insurance or pay a fine Will.
HIV and Aging Kathleen K Casey, MD Director, AIDS Ambulatory Care Center Jersey Shore University Medical Center.
Select a time to count down from the clock above
The Value of Medication Therapy Management Services.
The Transformative Effect of Quality Reporting Margaret E. O’Kane NCQA President April 11, 2005.
Better Health, Lower Health Costs: An Overview of the Asheville Model Right Care Initiative Scott Sproull, Vice President GlaxoSmithKline.
Disease State Management The Pharmacist’s Role
The Value of Medication Therapy Management Services.
The Value of Medication Therapy Management Services
Value Based Insurance Design Michael Chernew Feb 22, 2008 Portions of this research were funded by Pfizer and GSK.
Improving Medication Compliance Among College Students Presented to the American College Health Association May 31, 2012 by Benjamin F. Banahan III, Ph.D.,
* The Asheville Project * An Ounce of Prevention Really IS Worth a Pound of Cure Barry A. Bunting, Pharm.D. Clinical Manager of Pharmacy Services Mission.
Value-Based Insurance Design A “Clinically Sensitive” Approach to Preserve Quality of Care and Contain Cost.
The Value of Medication Therapy Management Services.
Value Based Insurance Design Michael Chernew Oct 10, 2008 Portions of this research were funded by Pfizer and GSK.
The Value of Medication Therapy Management Services.
Evaluating clinical pharmacist impact on diabetes control: outcomes on hemoglobin A1c Mark Amoo PharmD Candidate, Dalton Walsh PharmD Candidate, Kalyani.
COMMUNITY-BASED CASE MANAGEMENT OF HIGH RISK POPULATIONS DECREASES HEALTHCARE COSTS THE ASHEVILLE EXPERIENCE Barry A. Bunting, Pharm.D. Clinical Manager.
The Impact of Drug Benefit Design on Medication Adherence and Outcomes Michael C. Sokol, MD, MS Medical Director Health Management Innovations (c) 2008.
* Indicates p < 0.05 indicates p < 0.05 Evaluating Clinical Pharmacist Impact on Diabetes Control* Mary Ella Hill, Pharm. D. Candidate; Orijane Dalton,
The Value of Medication Therapy Management Services.
The Value of Medication Therapy Management Services.
Dr. Raymond J. Fabius, MD President & Chief Medical Officer CHD Meridian Healthcare Beyond Pharmacy Benefit Management: Pharmacy Clinical Leadership™ The.
Presentation Developed for the Academy of Managed Care Pharmacy
Cost-Effectiveness of Treatment Strategies for Comorbid Diabetes and Dyslipidemia Part 2.
3 The experiences of plan sponsors show a common theme: the investment in workforce health is founded on variability in cost sharing based on value.
New Opportunities in Medicare
Pharmaceutical care planning 2 Ola Ali Nassr
Presentation transcript:

Published Evidence for Value-Based Insurance Design Michael C. Sokol, MD, MS Corporate Medical Director Merck & Co., Inc.

Higher Prescription Co-Pays Associated with Lower Medication Adherence Kessler RC, Cantrell CR, Berglund P, Sokol MC. The effects of co-payments on medication adherence during the first two years of prescription drug treatment. Journal of Occupational and Environmental Medicine. 2007;49(6):

Relationship between Income and Medication Adherence Chernew M, Gibson TB, Yu-Isenberg K, Sokol MC, Rosen AB, Fendrick AM. Effects of Increased Patient Cost Sharing on Socioeconomic Disparities in Health Care. Journal of General Internal Medicine. 2008;23(8):

Employer Example- Service Industry Purpose of study: Examine the impact of lowering Rx co-pays on medication adherence 5 drug classes studied: ACE/ARBs, beta blockers, diabetes medications, statins, inhaled steroids Prospective, pre/post study with control group Time period: 2004 (pre) and 2005 (post) Both intervention and control groups used same disease management programs Chernew ME, Shah M, Wegh A, Rosenberg S, Juster IA, Rosen AB, Sokol MC, Yu-Isenberg K, Fendrick AM. Impact of Prescription Co-payments on Medication Adherence in the Context of a Disease Management Program. Health Affairs. 2008;27(1):

Lower Prescription Co-Pays Associated with Higher Medication Adherence Chernew ME, Shah M, Wegh A, Rosenberg S, Juster IA, Rosen AB, Sokol MC, Yu-Isenberg K, Fendrick AM. Impact of Prescription Co-payments on Medication Adherence in the Context of a Disease Management Program. Health Affairs. 2008;27(1):

Financial Outcomes of Intervention Program led to reduced use of nondrug health care services, offsetting costs associated with additional use of drugs encouraged by the program Thus, the intervention broke even (or even saved money) A targeted intervention, focusing on high-risk patients, would be even more favorable Indirect savings, such as productivity gains, could further offset the additional drug spending Chernew ME, Shah M, Wegh A, Rosenberg S, Juster IA, Rosen AB, Sokol MC, Yu-Isenberg K, Fendrick AM. Evidence that Value-Based Insurance Can Be Effective. Health Affairs. Web Exclusive Jan 2010.

Employer Example- City of Asheville, NC Purpose of study: To assess the persistence of outcomes for up to 5 years following the initiation of community-based pharmaceutical care services for patients with diabetes Education by certified diabetes educators, pharmacist follow-up using scheduled consultations, clinical assessment, goal setting, monitoring, and collaborative drug therapy management with physicians. Diabetes prescription co-pays and diabetic supplies waived for program participation Longitudinal prepost cohort study Time period: Cranor CW, Bunting BA, Christensen DB. The Asheville Project: Long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:

Higher Medication Adherence Associated with Lower Total Health Care Costs Cranor CW, Bunting BA, Christensen DB. The Asheville Project: Long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc. 2003;43:

Employer Example- Large Manufacturer Purpose of study: Examine the impact of medication adherence on hospitalization risk and health care cost 4 disease states studied- diabetes, high blood pressure, high cholesterol, heart failure Retrospective, observational study Time period: Diabetes – 3,260 patients in cohort – Average age was 54 years old – 45% female Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care. 2005;43:

Higher Medication Adherence Associated with Lower Total Health Care Costs Adherence level (% Days supply / 1 year) Average expenditures per patient per year ($) Average expenditures per patient per year ($) P< 0.05 Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care. 2005;43: $8,812$8,812 $6,959 $6,237 $5,887$3,808 $55 $165 $285 $404 $ %20-39%40-59%60-79%80-100% Rx $ Medical $ Diabetes Costs

Higher Medication Adherence Associated with Lower Hospitalization Rate 30* 26* 25* 20* Adherence level (%) Risk (%) Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Medical Care. 2005;43: *Indicates that outcome is significantly higher than outcome for % adherence group (P<0.05). Differences were tested for medical cost and hospitalization risk. Diabetes Hospitalization Risk